P
Prestige Biologics Co Ltd
KOSDAQ:334970
Prestige Biologics Co Ltd
KOSDAQ:334970
Price:
2 980
KRW
-0.33%
Market Closed
Market Cap:
₩231.7B
Income Statement
Earnings Waterfall
Prestige Biologics Co Ltd
Prestige Biologics Co Ltd
Income Statement
Prestige Biologics Co Ltd
Prestige Biologics Co Ltd
Currency: KRW
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||
| Interest Expense |
3 400
|
2 935
|
2 692
|
2 851
|
2 900
|
2 876
|
2 593
|
2 037
|
764
|
1 603
|
2 390
|
3 980
|
3 929
|
0
|
3 525
|
3 922
|
6 619
|
9 850
|
11 769
|
8 135
|
8 525
|
0
|
0
|
0
|
|
| Revenue |
185
N/A
|
185
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
150
N/A
|
407
+171%
|
3 227
+692%
|
3 227
N/A
|
3 077
-5%
|
2 834
-8%
|
16
-99%
|
69
+344%
|
1 730
+2 403%
|
2 646
+53%
|
3 396
+28%
|
3 981
+17%
|
2 169
-46%
|
1 597
-26%
|
3 869
+142%
|
6 711
+73%
|
12 533
+87%
|
13 359
+7%
|
|
| Gross Profit | |||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(283)
|
(405)
|
(873)
|
(873)
|
(590)
|
(478)
|
(12)
|
(54)
|
(1 213)
|
(1 284)
|
(2 613)
|
(6 785)
|
(10 856)
|
(15 927)
|
(24 377)
|
(24 172)
|
(28 219)
|
(25 582)
|
|
| Gross Profit |
185
N/A
|
185
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(133)
N/A
|
2
N/A
|
2 354
+106 514%
|
2 354
N/A
|
2 487
+6%
|
2 355
-5%
|
4
-100%
|
15
+315%
|
518
+3 367%
|
1 362
+163%
|
782
-43%
|
(2 804)
N/A
|
(8 687)
-210%
|
(14 330)
-65%
|
(20 508)
-43%
|
(17 461)
+15%
|
(15 686)
+10%
|
(12 223)
+22%
|
|
| Operating Income | |||||||||||||||||||||||||
| Operating Expenses |
(12 639)
|
(17 173)
|
(13 230)
|
(15 640)
|
(22 601)
|
(18 861)
|
(26 751)
|
(27 627)
|
(29 191)
|
(35 994)
|
(36 253)
|
(37 691)
|
(36 635)
|
(39 575)
|
(22 623)
|
(41 742)
|
(42 335)
|
(38 489)
|
(24 743)
|
(20 503)
|
(15 694)
|
(13 910)
|
(17 996)
|
(25 745)
|
|
| Selling, General & Administrative |
(3 369)
|
(4 527)
|
(2 356)
|
(2 516)
|
(3 810)
|
(1 963)
|
(4 174)
|
(4 066)
|
(3 860)
|
(3 743)
|
(3 877)
|
(4 665)
|
(5 394)
|
(6 120)
|
(4 558)
|
(10 497)
|
(10 552)
|
(10 924)
|
(10 270)
|
(8 336)
|
(9 380)
|
(11 043)
|
(9 631)
|
(9 123)
|
|
| Research & Development |
(7 078)
|
(11 218)
|
(10 321)
|
(12 477)
|
(16 114)
|
(15 697)
|
(21 326)
|
(22 374)
|
(24 394)
|
(30 995)
|
(30 717)
|
(30 798)
|
(30 970)
|
(31 412)
|
(17 385)
|
(29 230)
|
(28 834)
|
(23 232)
|
(9 301)
|
(6 431)
|
(205)
|
3 231
|
(1 429)
|
(12 471)
|
|
| Depreciation & Amortization |
(2 192)
|
(1 428)
|
(552)
|
(647)
|
(2 678)
|
(1 200)
|
(1 250)
|
(1 188)
|
(936)
|
(1 259)
|
(1 677)
|
(2 228)
|
(271)
|
(1 397)
|
(680)
|
(2 015)
|
(2 950)
|
(4 333)
|
(5 173)
|
(5 736)
|
(6 110)
|
(6 098)
|
(6 936)
|
(5 764)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
17
|
0
|
0
|
(646)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 613
|
|
| Operating Income |
(12 454)
N/A
|
(16 988)
-36%
|
(13 230)
+22%
|
(15 640)
-18%
|
(22 601)
-45%
|
(18 861)
+17%
|
(26 883)
-43%
|
(27 625)
-3%
|
(26 837)
+3%
|
(33 640)
-25%
|
(33 766)
0%
|
(35 336)
-5%
|
(36 631)
-4%
|
(39 560)
-8%
|
(22 105)
+44%
|
(40 380)
-83%
|
(41 553)
-3%
|
(41 294)
+1%
|
(33 430)
+19%
|
(34 833)
-4%
|
(36 202)
-4%
|
(31 370)
+13%
|
(33 682)
-7%
|
(37 968)
-13%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||
| Interest Income Expense |
(10 617)
|
(10 104)
|
(2 335)
|
(763)
|
(11 514)
|
(11 653)
|
(21 894)
|
(23 033)
|
(18 638)
|
(19 310)
|
(15 964)
|
(27 526)
|
(12 765)
|
(16 599)
|
(4 569)
|
409
|
(4 834)
|
(4 413)
|
(8 353)
|
(2 436)
|
(6 437)
|
(1 915)
|
1 633
|
(1 029)
|
|
| Non-Reccuring Items |
(7)
|
(11)
|
(17)
|
(25)
|
(33)
|
(32)
|
(41)
|
(70)
|
0
|
0
|
0
|
(592)
|
(646)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
63
|
66
|
0
|
0
|
(15)
|
0
|
0
|
91
|
0
|
(7)
|
(7)
|
(7)
|
(9)
|
|
| Total Other Income |
1 021
|
1 189
|
938
|
1 058
|
3 116
|
5 280
|
5 134
|
7 682
|
6 097
|
3 761
|
3 699
|
805
|
258
|
8 565
|
8 694
|
9 761
|
19 843
|
12 666
|
12 318
|
11 822
|
1 389
|
347
|
4 586
|
5 125
|
|
| Pre-Tax Income |
(22 057)
N/A
|
(25 913)
-17%
|
(14 644)
+43%
|
(15 370)
-5%
|
(31 033)
-102%
|
(25 266)
+19%
|
(43 685)
-73%
|
(43 046)
+1%
|
(39 378)
+9%
|
(49 189)
-25%
|
(46 036)
+6%
|
(62 586)
-36%
|
(49 718)
+21%
|
(47 594)
+4%
|
(17 980)
+62%
|
(30 225)
-68%
|
(26 544)
+12%
|
(33 041)
-24%
|
(29 374)
+11%
|
(25 447)
+13%
|
(41 257)
-62%
|
(32 945)
+20%
|
(27 469)
+17%
|
(33 881)
-23%
|
|
| Net Income | |||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(22 057)
|
(25 913)
|
(14 644)
|
(15 370)
|
(31 033)
|
(25 266)
|
(43 685)
|
(43 046)
|
(39 378)
|
(49 189)
|
(46 036)
|
(62 586)
|
(49 718)
|
(47 594)
|
(17 980)
|
(30 225)
|
(26 544)
|
(33 041)
|
(29 374)
|
(25 447)
|
(41 257)
|
(32 945)
|
(27 469)
|
(33 881)
|
|
| Net Income (Common) |
(22 057)
N/A
|
(25 913)
-17%
|
(14 644)
+43%
|
(15 370)
-5%
|
(31 033)
-102%
|
(25 266)
+19%
|
(43 685)
-73%
|
(43 046)
+1%
|
(39 378)
+9%
|
(49 189)
-25%
|
(46 036)
+6%
|
(62 586)
-36%
|
(49 718)
+21%
|
(47 594)
+4%
|
(17 980)
+62%
|
(30 225)
-68%
|
(26 544)
+12%
|
(33 041)
-24%
|
(29 374)
+11%
|
(25 447)
+13%
|
(41 257)
-62%
|
(32 945)
+20%
|
(27 469)
+17%
|
(33 881)
-23%
|
|
| EPS (Diluted) |
-693.86
N/A
|
-731.57
-5%
|
-413.42
+43%
|
-433.92
-5%
|
-876.12
-102%
|
-569.84
+35%
|
-961.45
-69%
|
-911.86
+5%
|
-885.98
+3%
|
-1 042
-18%
|
-972.86
+7%
|
-1 221.97
-26%
|
-960.73
+21%
|
-778.85
+19%
|
-294.23
+62%
|
-494.61
-68%
|
-433.85
+12%
|
-539.46
-24%
|
-479.5
+11%
|
-405.77
+15%
|
-532.91
-31%
|
-425.54
+20%
|
-372.51
+12%
|
-435.74
-17%
|
|
Switch to:
Switch to:
See Also
Discover More
